ZM241385

ZM241385 is a potent, high affinity and selective adenosine A2a receptor (A2AR) antagonist with a Ki value of 1.4 nM[1][2][3].

Product Specifications

CAS Number

[139180-30-6]

UNSPSC

12352005

Hazard Statement

H301

Target

Adenosine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/ZM241385.html

Purity

99.45

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC1=CC=C(CCNC2=NC3=NC(C4=CC=CO4)=NN3C(N)=N2)C=C1

Molecular Formula

C16H15N7O2

Molecular Weight

337.34

Precautions

H301

References & Citations

[1]Wang Z, et al. Static magnetic field exposure reproduces cellular effects of the Parkinson's disease drugcandidate ZM241385. PLoS One. 2010 Nov 8;5 (11) :e13883. doi: 10.1371/journal.pone.0013883.|[2]Linden J, et al. Characterization of human A (2B) adenosine receptors: radioligandbinding, western blotting, and coupling to G (q) in human embryonickidney 293 cells and HMC-1 mast cells. Mol Pharmacol. 1999 Oct;56 (4) :705-13.|[3]Poucher SM, et al. The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosinereceptor antagonist. Br J Pharmacol. 1995 Jul;115 (6) :1096-102.|[4]Ludwig S, et al. Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma. Cancer Immunol Immunother. 2019 Jul;68 (7) :1133-1141.